12 patents
Utility
Chemically Modified Oligonucleotides with Improved Systemic Delivery
23 Mar 23
The disclosure relates, in some aspects, to methods and compositions for targeting chemically-modified double stranded nucleic acid molecules to a site of interest, such as the liver.
James Cardia, Dingxue Yan
Filed: 31 Dec 20
Utility
Chemically Modified Oligonucleotides Targeting Bromodomain Containing Protein 4 (BRD4) for Immunotherapy
5 Jan 23
The disclosure relates, in some aspects, to methods and compositions for production of immunomodulatory compositions.
James Cardia, Rolf Kiessling, Jeroen Melief
Filed: 6 Nov 20
Utility
Immunotherapy of Cancer
11 Nov 21
Immunogenic modulators and compositions comprising oligonucleotide agents capable of inhibiting suppression of immune response by reducing expression of one or more gene involved with an immune response suppression mechanism.
Alexey Wolfson, Alexey Eliseev, Taisia Shmushkovich
Filed: 15 Jan 21
Utility
Methods for Treating Aging and Skin Disorders Using Nucleic Acids Targeting Tyr or MMP1
11 Nov 21
The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
Gerard Cauwenbergh
Filed: 15 Jan 21
Utility
Rna Interference In Dermal and Fibrotic Indications
26 Aug 21
The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
Filed: 15 Jan 21
Utility
Reduced Size Self-delivering Rnai Compounds
20 May 21
The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing.
Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
Filed: 21 Jul 20
Utility
Rna Interference In Ocular Indications
4 Mar 21
The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
Filed: 12 May 20
Utility
Rna Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality
30 Sep 20
The present invention relates to RNAi constructs and their use in gene silencing.
TOD M. WOOLF, JOANNE KAMENS, WILLIAM SALOMON, ANASTASIA KHVOROVA
Filed: 10 Nov 19
Utility
Chemically Modified Oligonucleotides
8 Jul 20
The disclosure relates, in some aspects, to methods and compositions for production of immunogenic compositions.
Alexey Eliseev
Filed: 6 Aug 18
Utility
Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition
1 Apr 20
The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections.
William R. Levis, Leonard L. Kaplan, John G. Callahan
Filed: 7 Apr 19
Utility
Topical Delivery of Nucleic Acid Compounds
18 Mar 20
In some aspects, the disclosure relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
Melissa Maxwell, Richard J. Looby
Filed: 18 Apr 18
Utility
Reduced Size Self-delivering Rnai Compounds
1 Jan 20
The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
Filed: 6 Feb 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first